Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer

Yamaguchi, Karen; Chikuda, Junichiro; Shirota, Tatsuo; Yamamoto, Yusuke

doi:10.3390/biom12020284

Cited by 8 publications

(2 citation statements)

References 213 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations have propelled efforts to elucidate the mechanisms that may be responsible for oral cancer chemotherapeutic resistance [ 3 , 4 ]. Although multiple mechanisms have been identified, many studies have now identified miRNAs as critical intermediaries that function to modulate many of the pathways closely associated with chemotherapeutic resistance among oral cancers [ 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

Recent advances have suggested that non-coding miRNAs (such as miR-21, miR-27, miR-145, miR-155, miR-365, miR-375 and miR-494) may be involved in multiple aspects of oral cancer chemotherapeutic responsiveness. This study evaluated whether these specific miRNAs are correlated with oral cancer responsiveness to chemotherapies, including Paclitaxel, Cisplatin and Fluorouracil (5FU). Commercially available and well-characterized oral squamous cell carcinoma cell lines (SCC4, SCC9, SCC15, SCC25 and CAL27) revealed differing resistance and chemosensitivity to these agents—with SCC9 and SCC25 demonstrating the most resistance to all chemotherapeutic agents. SCC9 and SCC25 were also the only cell lines that expressed miR-375, and were the only cell lines that did not express miR-27. In addition, the expression of miR-375 was associated with the upregulation of Rearranged L-myc fusion (RLF) and the downregulation of Centriolar protein B (POC1), whereas lack of miR-27 expression was associated with Nucleophosmin 1 (NPM1) expression. These data have revealed important regulatory pathways and mechanisms associated with oral cancer proliferation and resistance that must be explored in future studies of potential therapeutic interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, circRNA C190 overexpression facilitated the proliferation, and migration of non-small cell lung carcinoma (NSCLC) cell lines by targeting CDK1 and CDK6 via sequestrating miR-142-5p (17). Notably, ncRNA dysregulation contributes to the development of cancer drug resistance via various mechanisms, such as the inhibition of apoptosis, enhancement of epithelial-to-mesenchymal transition (EMT), and induction of autophagy (18)(19)(20). In addition, the differential expression patterns of ncRNAs endow them with great potential as biomarkers and therapeutic targets for cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.

show abstract